Should I buy or sell ProQR Therapeutics stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ProQR Therapeutics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" PRQR shares. View PRQR analyst ratings or view top-rated stocks .

What is ProQR Therapeutics' stock price target for 2024?

4 Wall Street analysts have issued 1-year price targets for ProQR Therapeutics' stock. Their PRQR share price targets range from $2.00 to $5.00. On average, they predict the company's stock price to reach $3.60 in the next twelve months. This suggests a possible upside of 81.4% from the stock's current price. View analysts price targets for PRQR or view top-rated stocks among Wall Street analysts .

How have PRQR shares performed in 2024?

ProQR Therapeutics' stock was trading at $1.98 at the beginning of the year. Since then, PRQR shares have increased by 0.3% and is now trading at $1.9850. View the best growth stocks for 2024 here .

When is ProQR Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 21st 2024. View our PRQR earnings forecast .

How were ProQR Therapeutics' earnings last quarter?

ProQR Therapeutics (NASDAQ:PRQR) released its quarterly earnings results on Wednesday, March, 13th. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.08). The biopharmaceutical company earned $3.54 million during the quarter, compared to analyst estimates of $27.88 million. ProQR Therapeutics had a negative net margin of 431.65% and a negative trailing twelve-month return on equity of 56.71%.

What ETF holds ProQR Therapeutics' stock?

Morningstar US Small Growth holds 21,680 shares of PRQR stock, representing 1.52% of its portfolio.

What other stocks do shareholders of ProQR Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ProQR Therapeutics investors own include (BIOA) (BIOA) , Galapagos (GLPG) , SCYNEXIS (SCYX) , TG Therapeutics (TGTX) , Verastem (VSTM) , Corbus Pharmaceuticals (CRBP) , Sorrento Therapeutics (SRNE) , uniQure (QURE) , Viking Therapeutics (VKTX) and Aldeyra Therapeutics (ALDX) .

Who are ProQR Therapeutics' major shareholders?

ProQR Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include RFG Advisory LLC (0.04%).

How do I buy shares of ProQR Therapeutics?

Shares of PRQR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:PRQR

ProQR Therapeutics (PRQR) Stock Price, News & Analysis

→ Bitcoin Rockets To Record High But Buy THIS Instead (From Paradigm Press) (Ad)

Free PRQR Stock Alerts

$1.98

+0.13 (+6.72%)

(As of 02:17 PM ET)

Compare

Today's Range: $1.87
▼
$2.07
50-Day Range: $1.86
▼
$2.56
52-Week Range: $1.11
▼
$3.29

Volume: 107,528 shs
Average Volume: 283,613 shs
Market Capitalization: $161.50 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $3.60

Get ProQR Therapeutics alerts:

ProQR Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 81.4% Upside
$3.60 Price Target
Short Interest: Healthy
0.50% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.76
Based on 4 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($0.37) to ($0.42) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.66 out of 5 stars

Medical Sector

625th out of 918 stocks

Pharmaceutical Preparations Industry

277th out of 418 stocks

3.5

Analyst's Opinion

Consensus Rating
ProQR Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
ProQR Therapeutics has only been the subject of 3 research reports in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
0.50% of the float of ProQR Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
ProQR Therapeutics has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in ProQR Therapeutics has recently decreased by 4.04%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
ProQR Therapeutics does not currently pay a dividend.
Dividend Growth
ProQR Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for PRQR.

2.6

News and Social Media Coverage

News Sentiment
ProQR Therapeutics has a news sentiment score of 0.76. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for ProQR Therapeutics this week, compared to 1 article on an average week.
MarketBeat Follows
Only 1 people have added ProQR Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, ProQR Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 8.40% of the stock of ProQR Therapeutics is held by insiders.
Percentage Held by Institutions
Only 32.65% of the stock of ProQR Therapeutics is held by institutions.

0.0

Earnings and Valuation

Earnings Growth
Earnings for ProQR Therapeutics are expected to decrease in the coming year, from ($0.37) to ($0.42) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of ProQR Therapeutics is -5.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of ProQR Therapeutics is -5.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
ProQR Therapeutics has a P/B Ratio of 3.61. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Paradigm Press

Bitcoin Rockets To Record High But Buy THIS Instead

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

>>Click here to find out what it is.

About ProQR Therapeutics Stock (NASDAQ:PRQR)

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2402, which focuses on Rett syndrome; AX-2911 for nonalcoholic steatohepatitis (NASH); AX-0601 for obesity and Type 2 diabetes; and AX-9115 for rare metabolic condition, as well as various other targets. In addition, the company develops Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center; Inserm Transfert SA; Ionis Pharmaceuticals, Inc.; Vico Therapeutics B.V.; University of Rochester; and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.

PRQR Stock Price History

30 days | 90 days | 365 days | Advanced Chart

PRQR Stock News Headlines

April 19, 2024 | globenewswire.com

ProQR Achieves Successful Defense of New Challenge to its Axiomer™ IP Portfolio

April 16, 2024 | americanbankingnews.com

ProQR Therapeutics (NASDAQ:PRQR) Shares Pass Above Fifty Day Moving Average of $2.16

April 19, 2024 | Stansberry Research (Ad)

Strange new buyer driving up gold

One Wall Street trader just made a big new gold prediction: "Pay attention to physical demand for gold... the interest seen over the last week has been unprecedented."

April 8, 2024 | finance.yahoo.com

ProQR Therapeutics N.V. (PRQR)

March 14, 2024 | markets.businessinsider.com

Buy Rating Affirmed: ProQR’s Axiomer Platform Shows Promising Potential in CNS and Metabolic Disorders

March 14, 2024 | markets.businessinsider.com

Buy Rating Affirmed for ProQR on Strong Financials and Promising RNA Editing Platform

March 14, 2024 | finance.yahoo.com

ProQR Therapeutics Full Year 2023 Earnings: Misses Expectations

March 13, 2024 | globenewswire.com

ProQR Announces Year End 2023 Operating and Financial Results

April 19, 2024 | Stansberry Research (Ad)

Strange new buyer driving up gold

One Wall Street trader just made a big new gold prediction: "Pay attention to physical demand for gold... the interest seen over the last week has been unprecedented."

February 18, 2024 | finance.yahoo.com

PRQR Mar 2024 2.500 call

February 16, 2024 | wsj.com

ProQR Therapeutics N.V.

February 15, 2024 | finance.yahoo.com

ProQR Announces Japanese Axiomer™ Patent Upheld Following Opposition Against Its Leading IP Estate for ADAR-mediated RNA Editing

January 30, 2024 | stocknews.com

4 Biotech Stocks With Massive Buy Potential

January 19, 2024 | finanznachrichten.de

ProQR Therapeutics N.V.: ProQR Highlights New Platform Data from Presentation on Axiomer RNA Editing Technology at Deaminet 2024

January 19, 2024 | finance.yahoo.com

ProQR Highlights New Platform Data from Presentation on Axiomer™ RNA Editing Technology at Deaminet 2024

January 15, 2024 | finance.yahoo.com

While institutions invested in ProQR Therapeutics N.V. (NASDAQ:PRQR) benefited from last week's 12% gain, individual investors stood to gain the most

January 6, 2024 | markets.businessinsider.com

Buy Rating Affirmed for ProQR on Strategic Partnership and Promising Axiomer RNA Editing Platform

January 5, 2024 | finanznachrichten.de

ProQR Therapeutics N.V.: ProQR and Rett Syndrome Research Trust Join Forces with Axiomer RNA Editing Collaboration

January 5, 2024 | benzinga.com

ProQR Therapeutics Stock (NASDAQ:PRQR) Dividends: History, Yield and Dates

January 5, 2024 | finance.yahoo.com

ProQR and Rett Syndrome Research Trust Join Forces with Axiomer™ RNA Editing Collaboration

December 28, 2023 | finance.yahoo.com

Is ProQR (PRQR) Stock a Solid Choice Right Now?

December 9, 2023 | markets.businessinsider.com

ProQR’s Strategic Divestiture and Strong Financial Outlook Justify Buy Rating

December 8, 2023 | finance.yahoo.com

ProQR Therapeutics Announces Transaction Completed for Théa to Acquire Sepofarsen and Ultevursen Ophthalmic Assets

November 21, 2023 | morningstar.com

ProQR Therapeutics NV PRQR

November 9, 2023 | markets.businessinsider.com

Positive Report for ProQR (PRQR) from Chardan Capital

November 9, 2023 | markets.businessinsider.com

Buy Rating for ProQR Therapeutics: Robust RNA-Editing Patent Portfolio, Promising Preclinical Candidates, and Strong Financial Position

November 8, 2023 | msn.com

Chardan Capital Upgrades ProQR Therapeutics N.V (PRQR)

See More Headlines

Receive PRQR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ProQR Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/13/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/21/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:PRQR
CUSIP: N/A
CIK: 1612940
Web: www.proqr.com
Phone: (188) 166-7000
Fax: N/A
Employees: 156
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $3.60
High Stock Price Target: $5.00
Low Stock Price Target: $2.00
Potential Upside/Downside: +81.4%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.39)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-30,430,000.00
Net Margins: -431.65%
Pretax Margin: -426.98%
Return on Equity: -56.71%
Return on Assets: -19.15%

Debt

Debt-to-Equity Ratio: 0.10
Current Ratio: 3.54
Quick Ratio: 3.54

Sales & Book Value

Annual Sales: $7.05 million
Price / Sales: 22.91
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.55 per share
Price / Book: 3.61

Miscellaneous

Outstanding Shares: 81,360,000
Free Float: 74,521,000
Market Cap: $161.50 million
Optionable: Optionable
Beta: 0.21

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

Dr. Domenico Valerio Ph.D. (Age 68)
Founder & Independent Chairman of Supervisory Board
Comp: $78.79k
Mr. Daniel Anton de Boer (Age 41)
Founder, CEO & Member of Management Board
Comp: $1.27M
Mr. Rene K. Beukema (Age 60)
Chief Corporate Development Officer, General Counsel & Member of Management Board
Comp: $974.24k
Dr. Gerard Platenburg (Age 60)
Co-Founder & Chief Scientific Officer
Comp: $23.42k
Mr. Jurriaan Dekkers (Age 48)
Chief Financial Officer
Ms. Sheila Sponselee (Age 40)
Chief People & Operations Officer
Ms. Sarah Cue Kiely
Vice President of Investor Relations & Corporate Communications
Ms. Sandra van der Kolk
Junior Financial Controller

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

PRQR Stock Analysis - Frequently Asked Questions

Should I buy or sell ProQR Therapeutics stock right now?: 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ProQR Therapeutics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" PRQR shares.
View PRQR analyst ratings or view top-rated stocks.
What is ProQR Therapeutics' stock price target for 2024?: 4 Wall Street analysts have issued 1-year price targets for ProQR Therapeutics' stock. Their PRQR share price targets range from $2.00 to $5.00. On average, they predict the company's stock price to reach $3.60 in the next twelve months. This suggests a possible upside of 81.4% from the stock's current price.
View analysts price targets for PRQR or view top-rated stocks among Wall Street analysts.
How have PRQR shares performed in 2024?: ProQR Therapeutics' stock was trading at $1.98 at the beginning of the year. Since then, PRQR shares have increased by 0.3% and is now trading at $1.9850.
View the best growth stocks for 2024 here.
When is ProQR Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 21st 2024.
View our PRQR earnings forecast.
How were ProQR Therapeutics' earnings last quarter?: ProQR Therapeutics (NASDAQ:PRQR) released its quarterly earnings results on Wednesday, March, 13th. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.08). The biopharmaceutical company earned $3.54 million during the quarter, compared to analyst estimates of $27.88 million. ProQR Therapeutics had a negative net margin of 431.65% and a negative trailing twelve-month return on equity of 56.71%.

What ETF holds ProQR Therapeutics' stock?: Morningstar US Small Growth holds 21,680 shares of PRQR stock, representing 1.52% of its portfolio.
What other stocks do shareholders of ProQR Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other ProQR Therapeutics investors own include (BIOA) (BIOA), Galapagos (GLPG), SCYNEXIS (SCYX), TG Therapeutics (TGTX), Verastem (VSTM), Corbus Pharmaceuticals (CRBP), Sorrento Therapeutics (SRNE), uniQure (QURE), Viking Therapeutics (VKTX) and Aldeyra Therapeutics (ALDX).
Who are ProQR Therapeutics' major shareholders?: ProQR Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include RFG Advisory LLC (0.04%).
How do I buy shares of ProQR Therapeutics?: Shares of PRQR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PRQR) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial